CD8A and neoplasm: The results suggest that the anti-tumor mechanism mediated by αCTLA-4 treatment in the IM vaccination may skew the neoantigen-specific immune response toward a CD8+IFNγ+ effector function whereas in the ID vaccination in the direction of CD4+TNFα+.